Jason A Konner

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma
    Jason Konner
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 30:2294-302. 2012
  2. doi request reprint Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study
    Jason A Konner
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5288-95. 2010
  3. doi request reprint A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
  4. pmc Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    Jason A Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:4662-8. 2011
  5. doi request reprint Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies
    Vaagn Andikyan
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Gynecol Cancer 23:923-8. 2013
  6. doi request reprint Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer
    Edward J Tanner
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 124:59-62. 2012
  7. doi request reprint Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:2690-7. 2008
  8. ncbi request reprint Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
    Paul J Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4170-7. 2007
  9. doi request reprint A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 14:6310-6. 2008
  10. doi request reprint Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study
    Martee L Hensley
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Gynecol Oncol 112:563-7. 2009

Collaborators

Detail Information

Publications18

  1. doi request reprint Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma
    Jason Konner
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 30:2294-302. 2012
    ..To determine the maximum tolerated dose and safety of the epothilone, KOS-862, in patients with advanced solid tumors or lymphoma...
  2. doi request reprint Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study
    Jason A Konner
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5288-95. 2010
    ..This phase I, dose-escalation study was conducted to determine the safety of weekly i.v. farletuzumab and establish the maximum tolerated dose (MTD)...
  3. doi request reprint A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
    ..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer...
  4. pmc Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    Jason A Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:4662-8. 2011
    ..Bevacizumab prolongs progression-free survival (PFS) when included in first-line IV chemotherapy. In this study, the safety and feasibility of adding bevacizumab to a first-line IP regimen were assessed...
  5. doi request reprint Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies
    Vaagn Andikyan
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Gynecol Cancer 23:923-8. 2013
    ..We conducted a retrospective review to evaluate the feasibility of administering adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies...
  6. doi request reprint Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer
    Edward J Tanner
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 124:59-62. 2012
    ..We hypothesize that patients who have received adjuvant IP chemotherapy more commonly recur first at extraperitoneal sites than patients who have received adjuvant intravenous (IV) chemotherapy...
  7. doi request reprint Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:2690-7. 2008
    ..The aim was to determine the long-term outcome for patients with FIGO stage IV epithelial ovarian carcinoma (EOC) treated with intraperitoneal (IP) chemotherapy after second-look assessment...
  8. ncbi request reprint Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
    Paul J Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4170-7. 2007
    ....
  9. doi request reprint A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 14:6310-6. 2008
    ..To determine the maximally tolerated dose (MTD) of biweekly pemetrexed with gemcitabine plus B(12) and folate supplementation in patients with advanced solid tumors and ovarian cancer...
  10. doi request reprint Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study
    Martee L Hensley
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Gynecol Oncol 112:563-7. 2009
    ..We sought to determine whether adjuvant gemcitabine-docetaxel would yield a 2-year progression-free survival of at least 50% in this leiomyosarcoma population...
  11. pmc Consolidation strategies in ovarian cancer: observations for future clinical trials
    Paul Sabbatini
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 116:66-71. 2010
    ..CONCLUSION.: Preliminary benchmarks for efficacy endpoints are suggested for future consolidation trials of patients in cCR. However, the suggested strategies will require validation in randomized trials and larger data sets...
  12. pmc Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003
    Peter M Smith-Jones
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Box 77, New York, NY 10021, USA
    Nucl Med Biol 35:343-51. 2008
    ..The in vitro and in vivo behavior of the radiolabeled monoclonal antibody MORAb-003 was investigated as a prelude to a clinical trial...
  13. doi request reprint A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer
    Dennis S Chi
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Oncologist 14:835-9. 2009
    ..To obtain prospective outcomes data on patients (pts) undergoing palliative operative or endoscopic procedures for malignant bowel obstruction due to recurrent ovarian cancer...
  14. ncbi request reprint A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission
    Douglas Levine
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 110:2448-56. 2007
    ..The current study was conducted to determine the effect of goserelin and bicalutamide on progression-free survival (PFS) in patients with epithelial ovarian cancer who were in second or greater complete disease remission...
  15. doi request reprint Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors
    Yevgeniy Balagula
    Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    Cancer 118:5078-83. 2012
    ..Inhibitors of mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus, have been associated with a high rate of skin eruptions, but their clinical and histopathologic characteristics have not been explored...
  16. doi request reprint Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma
    John P Diaz
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:335-9. 2010
    ..The objective of this study was to examine the incidence and management of bevacizumab-associated gastrointestinal (GI) perforations in patients with recurrent ovarian carcinoma...
  17. ncbi request reprint Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 4:S81-5. 2004
    ..VEGF Trap has demonstrated marked efficacy in halting angiogenesis and shrinking tumors in preclinical animal models and is currently being studied in phase I clinical trials in humans with advanced solid malignancies...
  18. ncbi request reprint Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer
    Catherine S M Diefenbach
    Gynecologic Medical Oncology, Department of Medicine, Howard 903, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 104:435-42. 2007
    ..In this study, we examined the frequency of serum elevation as well as the diagnostic and prognostic significance of this serum marker in endometrial cancer...